PMID- 19881255
OWN - NLM
STAT- MEDLINE
DCOM- 20100122
LR  - 20191111
IS  - 1880-0920 (Electronic)
IS  - 1347-4367 (Linking)
VI  - 24
IP  - 5
DP  - 2009
TI  - Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose 
      suppresses sEH expression.
PG  - 438-45
AB  - Soluble epoxide hydrolase (sEH) is a xenobiotic-metabolizing enzyme that 
      metabolizes epoxides to produce vicinal diols. Diabetes is a common pathological 
      condition which effects drug metabolism. This study, investigates changes in the 
      levels of sEH in mice with diabetes induced by streptozotocin (STZ). Diabetes 
      reduced the amount of sEH protein in the liver and insulin restored the level of 
      protein. The kidneys are a target of diabetes. Diabetes significantly decreased 
      levels of sEH protein and also mRNA. The distribution of sEH in the kidney was 
      studied with immunostaining. There was distinct staining in the proximal tubules 
      but not in the glomerulus or other regions. Diabetes is characterized by high 
      glucose concentrations that lead to increased production of reactive oxygen 
      species (ROS). High glucose suppressed sEH mRNA and protein expression in Hep3B 
      cells. NADPH oxidase is the main source of ROS generation in high glucose 
      condition. The NADPH oxidase inhibitor, diphenyleneiodonium chloride (DPIC), 
      inhibited decrease in sEH expression at high glucose and hydrogen peroxide 
      suppressed sEH expression. These findings indicate that diabetes reduces sEH 
      expression by inducing ROS and may have important effects on the metabolism of 
      xenobiotics and endogenous substrates of sEH.
FAU - Oguro, Ami
AU  - Oguro A
AD  - Nanobiotechnology Research Center and Department of Bioscience, School of Science 
      and Technology, Kwansei Gakuin University, Sanda, Japan.
FAU - Fujita, Natsuko
AU  - Fujita N
FAU - Imaoka, Susumu
AU  - Imaoka S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Drug Metab Pharmacokinet
JT  - Drug metabolism and pharmacokinetics
JID - 101164773
RN  - 0 (Onium Compounds)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - 6HJ411TU98 (diphenyleneiodonium)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Diabetes Mellitus, Experimental/metabolism
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Epoxide Hydrolases/biosynthesis/*metabolism
MH  - Glucose/*administration & dosage/pharmacology
MH  - Kidney/enzymology
MH  - Liver/enzymology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NADPH Oxidases/antagonists & inhibitors
MH  - Onium Compounds/pharmacology
MH  - RNA, Messenger/drug effects/metabolism
MH  - Reactive Oxygen Species/metabolism
EDAT- 2009/11/03 06:00
MHDA- 2010/01/23 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/01/23 06:00 [medline]
AID - JST.JSTAGE/dmpk/24.438 [pii]
AID - 10.2133/dmpk.24.438 [doi]
PST - ppublish
SO  - Drug Metab Pharmacokinet. 2009;24(5):438-45. doi: 10.2133/dmpk.24.438.